<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
CURRENT REPORT FOR ISSUERS SUBJECT TO THE
1934 REPORTING REQUIREMENTS
FORM 8-K
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) June 22, 2000
------------------------------
KING PHARMACEUTICALS, INC.
--------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Tennessee 0--24425 54-1684963
--------------------------------------------------------------------------------
(State or other jurisdiction (Commission (I.R.S. Employer
of incorporation) File Number) Identification No.)
501 Fifth Street, Bristol, Tennessee 37620
--------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (423) 989-8000
----------------------------
Not Applicable
--------------------------------------------------------------------------------
(Former name, former address and former fiscal year,
if changed since last report)
<PAGE> 2
INFORMATION TO BE INCLUDED IN THE REPORT
ITEM 5. OTHER EVENTS.
The distribution of a three for two stock split became effective June
21, 2000 for shareholders of record as of June 12, 2000, for the common stock of
King Pharmaceuticals, Inc., a Tennessee corporation. King is restating its
consolidated financial statements for the years ended December 31, 1997, 1998
and 1999, which appeared in its Form 10-K for the fiscal year ended December 31,
1999 to reflect the stock split. The restated consolidated financial statements
included in this filing consist of the following:
(a) Report of Independent Accountants.
(b) Consolidated Balance Sheets as of December 31, 1998 and 1999.
(c) Consolidated Statements of Operations for the years ended
December 31, 1997, 1998 and 1999.
(d) Consolidated Statements of Changes in Shareholders' Equity for
the years ended December 31, 1997, 1998 and 1999.
(e) Consolidated Statements of Cash Flows for the years ended
December 31, 1997, 1998 and 1999.
(f) Notes to Consolidated Financial Statements.
EXHIBIT INDEX
<TABLE>
<CAPTION>
Exhibit Description
------- -----------
<S> <C>
23(a) Consent of PricewaterhouseCoopers LLP
99(b) Consolidated Financial Statements
</TABLE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
KING PHARMACEUTICALS, INC.
Date: June 22, 2000
By: /s/ Brian G. Shrader
-----------------------------------------
Brian G. Shrader, Chief Financial Officer
-1-
